FDA Accepts Giredestrant NDA for ESR1-Mutated Breast Cancer
Giredestrant NDA has been accepted by the U.S. Food and Drug Administration for review in patients with ESR1-mutated, ER-positive advanced breast cancer. Genentech, a member of the Roche Group,...

